Anti-fibrotic Activity of AVID200, a novel TGF-beta 1 & 3 inhibitor, to be Featured in an Oral Presentation at the Upcoming Keystone Symposia on NASH and NAFLD

Forbius, a clinical-stage company developing biologics for the treatment of cancer and fibrosis, announced that its Chief Scientific Officer, Maureen O’Connor, will be giving an oral presentation reporting on AVID200’s broad activity in fibrotic diseases at the Keystone Symposia on Integrated Pathways of Disease in NASH and NAFLD.